Silibinin suppresses growth of human prostate carcinoma PC-3 orthotopic xenograft via activation of extracellular signal-regulated kinase 1/2 and inhibition of signal transducers and activators of transcription signaling

Clinical Cancer Research

Volumn 15, Issue 2, 2009, Pages 613-621

  Singh, Rana P ^a,d   Raina, Komal ^a   Deep, Gagan ^a   Chan, Daniel ^b,c   Agarwal, Rajesh ^a,c,e  

^a TEXAS TECH UNIVERSITY HEALTH SCIENCES CENTER   (United States)

^b West Indies

^c UNIVERSITY OF COLORADO CANCER CENTER   (United States)

^d JAWAHARLAL NEHRU UNIVERSITY   (India)

^e UNIVERSITY OF COLORADO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE 3; CYCLIN A; CYCLIN D1; CYCLIN D3; CYCLIN DEPENDENT KINASE 1; CYCLIN DEPENDENT KINASE 2; CYCLIN DEPENDENT KINASE 4; CYCLIN DEPENDENT KINASE 6; CYCLIN E; CYCLINE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE 9; MITOGEN ACTIVATED PROTEIN KINASE P38; PROTEIN KINASE B; SILIBININ; STAT1 PROTEIN; STAT3 PROTEIN; STAT5 PROTEIN; STRESS ACTIVATED PROTEIN KINASE 1; VASCULOTROPIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN EXPRESSION; APOPTOSIS; ARTICLE; CELL CYCLE PROGRESSION; CELL PROLIFERATION; CONTROLLED STUDY; DRUG EFFICACY; DRUG INHIBITION; DRUG MECHANISM; ENZYME ACTIVATION; ENZYME PHOSPHORYLATION; HUMAN; HUMAN CELL; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTATE CARCINOMA; PROTEIN EXPRESSION; TREATMENT DURATION; XENOGRAFT;

ANIMALS; ANTIGENS, CD31; ANTIOXIDANTS; CASPASE 3; CELL LINE, TUMOR; HUMANS; MALE; MICE; MICE, NUDE; MITOGEN-ACTIVATED PROTEIN KINASE 1; MITOGEN-ACTIVATED PROTEIN KINASE 3; NEOPLASM TRANSPLANTATION; PROSTATIC NEOPLASMS; SILYMARIN; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 59449097284     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-08-1846     Document Type: Article

References (42)

1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2008. CA Cancer J Clin 2008;58:71-96.
2. Koivisto P, Kolmer M, Visakorpi T, Kallioniemi OP. Androgen receptor gene and hormonal therapy failure of prostate cancer. Am J Pathol 1998;152:1-9.
3. Feldman B J, Feldman D. The development of andro-gen-independent prostate cancer. Nat Rev Cancer 2001;1:34-45.
4. Agarwal R. Cell signaling and regulators of cell cycle as molecular targets for prostate cancer prevention by dietary agents. Biochem Pharmacol 2000;60:1051-9.
5. Singh RP, Agarwal R. Prostate cancer chemopreven-tion by silibinin: bench to bedside. Mol Carcinog 2006;45:436-42.
6. Singh RP, Agarwal R. Prostate cancer prevention by silibinin. Curr Cancer Drug Targets 2004;4:1-11.
7. Wellington K, Jarvis B. Silymarin: a review of its clinical properties in the management of hepatic disorders. Bio Drugs 2001;15:465-89.
8. Teicher BA. Tumor models for efficacy determination. Mol CancerTher 2006;5:2435-43.
9. Céspedes MV, Casanova I, Parreno M, Mangues R. Mouse models in oncogenesis and cancer therapy. Clin TransI Oncol 2006;8:318-29.
10. Kelloff GJ, Lieberman R, Steele VE, et al. Chemopre-vention of prostate cancer: concepts and strategies. Eur Urol 1999;35:342-50.
11. Surh YJ. Cancer chemoprevention with dietary phy-tochemicals. Nat Rev Cancer 2003;3:768-80.
12. Bosland MC, McCormick DL, Melamed J, Walden PD, Zeleniuch-Jacquotte A, Lumey LH. Chemoprevention strategies for prostate cancer. Eur J Cancer Prev 2002;11:S18-27.
13. Agarwal C, Singh RP, Dhanalakshmi S, et al. Silibinin up-regulates the expression of cyclin-dependent kinase inhibitors and causes cell cycle arrest and apoptosis in human colon carcinoma HT-29 cells. Oncogene 2003:22:8271-82.
14. Flaig TW, Gustafson DL, Su LJ, et al. A phase I pharmacokinetic study of silybin-phytosome in prostate cancer patients. Invest New Drugs 2007;25:139-46.
15. 1 arrest, leading to differentiation of prostate carcinoma cells: implications for prostate cancer intervention. Proc Natl Acad Sci USA 1999;96:7490-5.
16. Dhanalakshmi S, Singh RP, Agarwal C, Agarwal R. Silibinin inhibits constitutive and TNFα-induced activation of NF-κB and sensitizes human prostate carcinoma DU145 cells to TNFα-induced apoptosis. Oncogene 2002;21:1759-67.
17. 2-M cell cycle arrest via distinct circuitries in human prostate cancer PC3 cells: a comparison of flavanone silibinin with fla-vanolignan mixture silymarin. Oncogene 2006;25:1053-69.
18. Zi X, Zhang J, Agarwal R, Pollak M. Silibinin up-regulates insulin-like growth factor-binding protein 3 expression and inhibits proliferation of androgen-inde-pendent prostate cancer cells. Cancer Res 2000;60:5617-20.
19. Singh RP, Dhanalakshmi S, Tyagi AK, Chan DC, Agarwal C, Agarwal R. Dietary feeding of silibinin inhibits advance human prostate carcinoma growth in athymic nude mice and increases plasma insulin-like growth factor-binding protein-3 levels. Cancer Res 2002;62:3063-9.
20. Singh RP, Sharma G, Dhanalakshmi S, Agarwal C, Agarwal R. Suppression of advanced human prostate tumor growth in athymic mice by silibinin feeding is associated with reduced cell proliferation, increased apoptosis, and inhibition of angiogenesis. Cancer Epidemiol Biomarkers Prev 2003;12:933-9.
21. Singh RP, Deep G, Blouin MJ, Pollak MN, Agarwal R. Silibinin suppresses in vivo growth of human prostate carcinoma PC-3 tumor xenograft. Carcinogenesis 2007;28:2567-74.
22. Raina K, Blouin MJ, Singh RP, et al. Dietary feeding of silibinin inhibits prostate tumor growth and progression in transgenic adenocarcinoma of the mouse prostate model. Cancer Res 2007;67:11083-91.
23. Zhong W, Peng J, He H, et al. Ki-67 and PCNA ex-pression in prostate cancer and benign prostatic hyperplasia. Clin Invest Med 2008;31:E8-15.
24. Gurumurthy S, Vasudevan KM, Rangnekar VM. Regulation of apoptosis in prostate cancer. Cancer Metastasis Rev 2001;20:225-43.
25. Singh RP, Agarwal R. Tumor angiogenesis: a potential target in cancer control by phytochemicals. Curr Cancer Drug Targets 2003;3:205-17.
26. Berthet C, Kaldis P. Cell-specific responses to loss of cyclin-dependent kinases. Oncogene 2007;26:4469-77.
27. Santamaria D, Ortega S. Cyclins and CDKS in development and cancer: lessons from genetically modified mice. Front Biosci 2006;11:1164-88.
28. Rubinfeld H, Seger R. The ERK cascade: a prototype of MAPK signaling. Mol Biotechnol 2005;31:151-74.
29. Bodo J, Duraj J, Jakubikova J, Sedlak J. Isothio-cyanate E-4IB induces MAPK activation, delayed cell cycle transition and apoptosis. Cell Prolif 2007;40:316-26.
30. Mallikarjuna G, Singh RP, Dhanalakshmi S, Agarwal C, Agarwal R. Silibinin protects against photocar-cinogenesis via modulation of cell cycle regulators, mitogen-activated protein kinases, and Akt signaling. Cancer Res 2004;64:6349-56.
31. Haura EB, Turkson J, Jove R. Mechanisms of disease: insights into the emerging role of signal transducers and activators of transcription in cancer. Nat Clin Pract Oncol 2005;2:315-24.
32. Ni Z, Lou W, Leman ES, Gao AC. Inhibition of con-stitutively activated Stat3 signaling pathway suppresses growth of prostate cancer cells. Cancer Res 2000;60:1225-8.
33. Singh RP, Agarwal R. Mechanisms of action of novel agents for prostate cancer chemoprevention. Endocr Relat Cancer 2006;13:751-78.
34. Naumov GN, Akslen LA, Folkman J. Role of angiogenesis in human tumor dormancy: animal models of the angiogenic switch. Cell Cycle 2006;5:1779-87.
35. Singh RP, Dhanalakshmi S, Agarwal C, Agarwal R. Silibinin strongly inhibits growth and survival of human endothelial cells via cell cycle arrest and down-regulation of survivin, Akt and NF-κB: implications for angioprevention and antiangiogenic therapy. Oncogene 2005;24:1188-202.
36. Singh RP, Dhanalakshmi S, Agarwal R. Phytochem-icals as cell cycle modulators: a less toxic approach in halting human cancer. Cell Cycle 2002;1:156-61.
37. Fu M, Wang C, Li Z, Sakamaki T, Pestell RG. Minire-view: cyclin D1: normal and abnormal functions. Endocrinology 2004;145:5439-47.
38. 2-M arrest, and apoptosis. Clin Cancer Res 2002;8:3512-9.
39. Majumder PK, Sellers WR. Akt-regulated pathways in prostate cancer. Oncogene 2005;24:7465-74.
40. Horinaga M, Okita H, Nakashima J, Kanao K, Sakamoto M, Murai M. Clinical and pathologic significance of activation of signal transducer and acti-vator of transcription 3 in prostate cancer. Urology 2005;66:671-5.
41. Gao B, Shen X, Kunos G, et al. Constitutive activation of JAK-STAT3 signaling by BRCA1 in human prostate cancer cells. FEBS Lett 2001;488:179-84.
42. Agarwal C, Tyagi A, Kaur M, Agarwal R. Silibinin inhibits constitutive activation of Stat3, and causes caspase activation and apoptotic death of human prostate carcinoma DU145 cells. Carcinogenesis 2007;28:1463-70.